Calamos Advisors
NKTR icon

Calamos Advisors’s Nektar Therapeutics NKTR Stock Holding History

Calamos Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-3,091
Closed -$535K – 620
2013
Q2 		$535K Buy
+3,091
New +$474K ﹤0.01% 527

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Calamos Advisors's NKTR Position: Q3 2013 in Review

Calamos Advisors sold out of Nektar Therapeutics (NKTR) in Q3 2013, closing a stake of 3,091 shares — an estimated $535K sold.

Calamos Advisors first reported a position in NKTR in Q2 2013 and held it in 1 quarter. The position peaked at $535K in Q2 2013. 142 funds tracked by Wall St. Rank hold NKTR as of Q3 2013.

  • Calamos Advisors reported no remaining Nektar Therapeutics position as of Q3 2013 after selling out during the quarter.
  • Calamos Advisors sold 3,091 Nektar Therapeutics shares in Q3 2013, an estimated $535K.
  • Calamos Advisors first reported a position in Nektar Therapeutics in Q2 2013 and held it in 1 quarter.
  • Calamos Advisors's Nektar Therapeutics position peaked at $535K in Q2 2013.
  • 142 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2013.

Based on Calamos Advisors's 13F filing for Q3 2013, filed 14 Nov 2013.